Q3695734 (Q3695734): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): The implementation of recent advances on nanotechnologies in biology will lead to new opportunities in both diagnosis and therapy of major scourges (cardiovascular diseases, cancer, Alzheimer’s disease, etc.). In the Burgundy Franche-Comté region, the response to this challenge mobilises in a coordinated way the University of Burgundy Franche-Comté (UBFC), INSERM, the CHU de Dijon, the George-François Leclerc Cancer Centre (CGFL), companies in B...) |
||||||||||||||
| Property / summary | |||||||||||||||
The implementation of recent advances on nanotechnologies in biology will lead to new opportunities in both diagnosis and therapy of major scourges (cardiovascular diseases, cancer, Alzheimer’s disease, etc.). In the Burgundy Franche-Comté region, the response to this challenge mobilises in a coordinated way the University of Burgundy Franche-Comté (UBFC), INSERM, the CHU de Dijon, the George-François Leclerc Cancer Centre (CGFL), companies in Burgundy-Franche-Comté and France and the SATT Grand-Est. The Nano2bio project establishes a strong link between fundamental nanotechnology/nanomaterial research and potential end-users. Operation Nano2bio 2017 is part of the NANO2BIO regional project, which aims to integrate the components of a multidisciplinary basic research (biology-medicine, chemistry, physics) to create original combinations and guarantee the CFB region a high level of international competitiveness. This competitiveness is the prerequisite for anticipating patent filings and translating research results into industrial opportunities. (English) | |||||||||||||||
| Property / summary: The implementation of recent advances on nanotechnologies in biology will lead to new opportunities in both diagnosis and therapy of major scourges (cardiovascular diseases, cancer, Alzheimer’s disease, etc.). In the Burgundy Franche-Comté region, the response to this challenge mobilises in a coordinated way the University of Burgundy Franche-Comté (UBFC), INSERM, the CHU de Dijon, the George-François Leclerc Cancer Centre (CGFL), companies in Burgundy-Franche-Comté and France and the SATT Grand-Est. The Nano2bio project establishes a strong link between fundamental nanotechnology/nanomaterial research and potential end-users. Operation Nano2bio 2017 is part of the NANO2BIO regional project, which aims to integrate the components of a multidisciplinary basic research (biology-medicine, chemistry, physics) to create original combinations and guarantee the CFB region a high level of international competitiveness. This competitiveness is the prerequisite for anticipating patent filings and translating research results into industrial opportunities. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The implementation of recent advances on nanotechnologies in biology will lead to new opportunities in both diagnosis and therapy of major scourges (cardiovascular diseases, cancer, Alzheimer’s disease, etc.). In the Burgundy Franche-Comté region, the response to this challenge mobilises in a coordinated way the University of Burgundy Franche-Comté (UBFC), INSERM, the CHU de Dijon, the George-François Leclerc Cancer Centre (CGFL), companies in Burgundy-Franche-Comté and France and the SATT Grand-Est. The Nano2bio project establishes a strong link between fundamental nanotechnology/nanomaterial research and potential end-users. Operation Nano2bio 2017 is part of the NANO2BIO regional project, which aims to integrate the components of a multidisciplinary basic research (biology-medicine, chemistry, physics) to create original combinations and guarantee the CFB region a high level of international competitiveness. This competitiveness is the prerequisite for anticipating patent filings and translating research results into industrial opportunities. (English) / qualifier | |||||||||||||||
point in time: 22 November 2021
| |||||||||||||||
Revision as of 10:33, 22 November 2021
Project Q3695734 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3695734 in France |
Statements
83,012.55 Euro
0 references
200,654.8 Euro
0 references
41.37 percent
0 references
21 February 2017
0 references
30 November 2019
0 references
Université de Bourgogne
0 references
La mise en œuvre des avancées récentes sur les nanotechnologies en biologie débouchera sur de nouvelles opportunités tant au niveau du diagnostic que de la thérapie de fléaux majeurs (maladies cardio-vasculaires, cancer, maladie d'Alzheimer...). En région Bourgogne Franche-Comté, la réponse à ce défi mobilise de façon coordonnée l'Université de Bourgogne Franche-Comté (UBFC), l'INSERM, le CHU de Dijon, le centre de cancérologie George-François Leclerc (CGFL), des entreprises en Bourgogne-Franche-Comté et en France et ainsi que la SATT Grand-Est. Le projet Nano2bio établit un lien fort entre recherches fondamentales en nanotechnologies/nanomatériaux et les utilisateurs finaux potentiels. L’opération Nano2bio 2017 s’intègre dans le projet régional NANO2BIO qui vise à intégrer les composantes d'une recherche fondamentale pluridisciplinaire (biologie-médecine, chimie, physique) pour créer des combinaisons originales et garantir à la région BFC un haut niveau de compétitivité sur la scène internationale. Cette compétitivité est la condition pour anticiper les dépôts de brevets et traduire les résultats des activités de recherche en opportunités industrielles. (French)
0 references
The implementation of recent advances on nanotechnologies in biology will lead to new opportunities in both diagnosis and therapy of major scourges (cardiovascular diseases, cancer, Alzheimer’s disease, etc.). In the Burgundy Franche-Comté region, the response to this challenge mobilises in a coordinated way the University of Burgundy Franche-Comté (UBFC), INSERM, the CHU de Dijon, the George-François Leclerc Cancer Centre (CGFL), companies in Burgundy-Franche-Comté and France and the SATT Grand-Est. The Nano2bio project establishes a strong link between fundamental nanotechnology/nanomaterial research and potential end-users. Operation Nano2bio 2017 is part of the NANO2BIO regional project, which aims to integrate the components of a multidisciplinary basic research (biology-medicine, chemistry, physics) to create original combinations and guarantee the CFB region a high level of international competitiveness. This competitiveness is the prerequisite for anticipating patent filings and translating research results into industrial opportunities. (English)
22 November 2021
0 references
Identifiers
BG0013211
0 references